Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for ALK-positive anaplastic large cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
ECHELON-2 enrolled CD30-positive peripheral T-cell lymphoma and was weighted towards anaplastic large cell lymphoma, so the benefit in the other CD30-positive entities is extrapolated rather than demonstrated.
Whether an ALK inhibitor should be added to first-line treatment, or substituted for part of it, has not been tested in a randomised trial.
Most of the ALK-positive patients are young, and the late effects of anthracycline chemotherapy in a cured 30-year-old are measured in decades and are not recorded in the trials.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone, on the strength of ECHELON-2, which randomised 452 people with untreated CD30-positive peripheral T-cell lymphoma, three-quarters of them with systemic anaplastic large cell lymphoma: five-year progression-free survival 51.4 per cent against 43.0 and overall survival 70.1 against 61.0 with chemotherapy alone. Vincristine is left out because brentuximab vedotin is itself a tubulin-directed agent and giving both causes unacceptable nerve damage. Unlike the other nodal T-cell lymphomas, ALK-positive disease does well enough that consolidating a first remission with an autologous transplant is generally not offered. The regimens and the cycle detail are on the peripheral T-cell lymphoma page.
Immunohistochemistry for CD30 and for ALK protein on the biopsy, with fluorescence in situ hybridisation to confirm the rearrangement where the stain is equivocal. The large pleomorphic cells, the frequent expression of epithelial membrane antigen and the loss of several T-cell markers mean that a tumour stained with a short panel can be reported as a carcinoma or a sarcoma; CD30 and ALK are what prevent that. Staging covers the sites this disease reaches outside the lymph nodes: skin, bone, soft tissue, lung and liver.
In 452 patients with CD30-positive peripheral T-cell lymphoma, three-quarters of them with systemic anaplastic large cell lymphoma, five-year progression-free survival was 51.4 per cent with brentuximab vedotin and chemotherapy against 43.0 per cent with chemotherapy alone, and overall survival 70.1 against 61.0 per cent.
A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.
The CD30 antibody-drug conjugate was approved for systemic anaplastic large cell lymphoma after failure of previous treatment, on high response rates in a small single-arm trial.